Navigation Links
Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer

ORLANDO, Fla., April 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer.  The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.  

Signaling pathways within cells regulate genes that underlie crucial biological processes including cell division, embryonic development and immunity.  When these networks of proteins misfire, many types of cancer can result.  At AACR, data from Lilly showed how these pipeline molecules target out-of-control signaling pathways.

"Lilly is focused on developing therapies tailored for an individual patient's needs – such as a cancer treatment that targets a specific genetic mutation," said Jonathan M. Yingling, Ph.D., vice president of oncology research at Lilly.  "We believe beginning this evaluation early in the preclinical stage, as we have with these two studies, may lead to more focused, efficient clinical trials and, in turn, speed drug discovery."

LY2784544: JAK2 Inhibitor (Abstract # 2820)

Research presented at AACR's New Small Molecule Therapeutics mini-symposium suggested that the investigational compound LY2784544, a small-molecule JAK2 inhibitor, blocks a specific, difficult-to-isolate, signaling pathway that can lead to the development of cancer cells.  

Specifically, Lilly researchers chose to study inflammatory breast cancer (IBC) cells because these cells support their own survival by secreting chemicals known as growth factors, which allow them to break away from the primary tumor, multiply and then cluster together into tumor spheres – ultimately metastasizing, or spreading.

Lilly scientists focused on a growth factor called IL-6, which latches onto receptors on the surface of cells and triggers the IL-6–JAK–STAT3 signaling pathway, promoting formation of the deadly IBC cell clusters by activating the STAT3 protein, which then turns on the genes that encourage IBC cells to stick together.  

Researchers hypothesized that short-circuiting the IL-6–JAK–STAT3 pathway could prevent the formation of tumor cell clusters.  The scientists first cultured the tumor spheres in medium containing IL-6.  As expected, IL-6 activated STAT3, the cells proliferated, and the tumor spheres grew.  Furthermore, expression of IL-6 by the spheres themselves increased by 50-fold; and secretion of intracellularly produced IL-6 activated STAT3, and prevented cell death in the tumor spheres.

But when Lilly's JAK2 inhibitor was added to the medium containing the tumor spheres, the scientists found that it inhibited STAT3 activation in a dose-dependent manner and that blocking this signaling pathway induced cell death in the tumor spheres.  The IL-6–JAK–STAT3 pathway may serve as a "molecular signature" of IBC and as a potential therapeutic target.

Lilly's JAK2 inhibitor is currently being evaluated in Phase I clinical trials for the treatment of myeloproliferative neoplasms, or diseases of the blood and bone marrow, called polycythemia vera, essential thrombocythemia and myelofibrosis.  

LY2940680: Halting Abnormal Signaling via the Hedgehog Pathway (Abstract # 2819)

Lilly scientists have identified an orally administered anti-cancer agent, LY2940680, which, in preclinical studies, disrupted the abnormal signaling of a key regulator of embryonic cell development. Data was also presented at AACR's New Small Molecule Therapeutics mini-symposium.  

This novel molecule has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein, which is essential for regulating normal cell differentiation and proliferation.  Abnormal Hh signaling has been implicated in several types of cancer, including brain, lung, breast, prostate and skin cancers.  Abnormal Hh pathway activation can result from genetic mutations in the pathway's protein components.

One such protein component, known as Smoothened (Smo), is a key regulator of the Hh signaling pathway and is seen as a potential target for therapies aimed at treating cancer by halting abnormal Hh signaling.

Lilly scientists have identified that Lilly's Hedgehog inhibitor is a small molecule antagonist of Smo, binding to it and inhibiting Hh signaling in a human medulloblastoma tumor cell.  (Medulloblastoma is the most commonly diagnosed form of brain tumor in children, but is rare in adults.(1))  In addition, when the compound was orally administered to transgenic mice that spontaneously develop medulloblastoma, it improved animal survival.

Lilly's Hedgehog inhibitor is currently being studied in Phase I clinical trials for solid tumors.

About Preclinical Data

The compounds discussed in this press release are investigational. Their safety and efficacy in humans have not been established.

About Lilly Oncology

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer.  Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches.  To learn more about Lilly's commitment to cancer, please visit  

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.


This press release contains forward-looking statements about the potential of LY2784544 and LY2940680 and reflects Lilly's current beliefs. However, as with any pharmaceutical compound, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that either compound will be approved by the relevant regulatory authorities or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(1) Brandes AA, Ermani M, Amista P, et al.: The treatment of adults with medulloblastoma: a prospective study. Int J Radiat Oncol Biol Phys 57 (3): 755-61, 2003.


SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Doctors who missed a case of mesothelioma ... signs of mesothelioma and push for a diagnosis, especially in people exposed to asbestos. ... here to read it now. , Researchers at Gifu Prefectural Tajimi Hospital ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may ... one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there ... save the expense of having to replace NuvaRings more often than necessary. As such, ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... to be a safe and convenient way to dispense prescription medications at home, ... safe and effective way to monitor and dispense prescription medications. In doing so, ...
(Date:11/27/2015)... ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating ... of 30 (see Table 1-1 ). More than 3.7 billion people under the ... virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . ...
Breaking Medicine News(10 mins):